SCHEDULE: T. Rowe Price Discloses Stake in Dyne Therapeutics

T. Rowe Price Investment Management, Inc. has reported a significant beneficial ownership stake of 18.7% in Dyne Therapeutics Inc., as of March 31, 2026.

Summary

• T. Rowe Price Investment Management, Inc. has filed a Schedule 13G, indicating beneficial ownership of Dyne Therapeutics Inc. common stock.
• The filing, dated March 31, 2026, shows T. Rowe Price Investment Management, Inc. holds 30,785,801 shares, representing 18.7% of the class.
• The reporting entity has sole voting power over 30,419,012 shares and sole dispositive power over 30,785,801 shares.
• T. Rowe Price Investment Management, Inc. is identified as an investment adviser and not acting to influence or control the issuer.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive signal, as a large investment firm taking a significant passive stake suggests confidence in the company's underlying value, though it doesn't directly comment on operational performance.

Positives

• Significant investment by a major asset manager (T. Rowe Price) suggests confidence in Dyne Therapeutics' long-term prospects.
• The 18.7% stake indicates substantial conviction in the company's value proposition.

Negatives

• The filing is a Schedule 13G, which is an informational filing for passive investors, and does not inherently signal positive or negative performance of the company itself.
• T. Rowe Price expressly denies beneficial ownership for the purpose of influencing control, indicating a passive investment stance.

Risks

• As a passive investment, the filing does not detail specific risks related to Dyne Therapeutics' operations or pipeline.
• The primary risk is inherent to Dyne Therapeutics' business, which is not elaborated upon in this filing.

Future Outlook

This filing is a disclosure of ownership and does not contain forward-looking statements or guidance from Dyne Therapeutics Inc.

Management Comments

• T. Rowe Price Investment Management, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Investment Management is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

Industry Context

StockSavvy.ai notes that significant passive stakes by large asset managers like T. Rowe Price in biotechnology companies often reflect a belief in the company's scientific platform and potential for future drug development success, especially in areas like rare genetic diseases where Dyne Therapeutics operates.

Stakeholder Impact

• Shareholders may view the significant stake by T. Rowe Price as a positive endorsement, potentially increasing investor confidence.
• The passive nature of the investment means no immediate impact on corporate control or strategic direction is implied.

Next Steps

• Continued monitoring of Dyne Therapeutics' clinical trial progress and regulatory milestones.
• Observation of any future changes in T. Rowe Price's beneficial ownership.

Key Dates

Keywords

Dyne Therapeutics, T. Rowe Price, Schedule 13G, Beneficial Ownership, Investment Management, Common Stock, SEC Filing, Biotechnology, Pharmaceuticals